Serious bleeding is a major cause of morbidity and mortality worldwide and outcomes are linked to how quickly hemostasis can be achieved. Excessive bleeding is a global threat that can affect all populations, but is especially critical for patients on anticoagulant therapy or those who have a rare bleeding disorder. Cayuga Biotech’s mission is to harness the potential of polyphosphate to address uncontrolled bleeding episodes.

CAY001 is a first-in-class drug which aims to accelerate the body’s natural clotting response even in patients with compromised platelet function. Unlike natural platelets, CAY001 is can be mass-manufactured, is stable at room temperature, and does not require type matching, allowing it to be deployed with first responders.